Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution Failure in Chronic HIV-1 Infected Patients

NCT02648516 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT02648516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02648516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution Failure in Chronic HIV-1 Infected Patients
Lead sponsor
Beijing 302 Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
December 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

disorder of immune reconstitution, human immunodeficiency virus